Loading
When a BCMA drug stops working, switching to a drug against a different myeloma protein still produces responses in about two-thirds of patients.
When a BCMA-directed therapy such as teclistamab stops working in multiple myeloma, switching to the GPRC5D-directed bispecific talquetamab is a sequence pairing that still produces responses in a majority of patients. GPRC5D is an independent antigen with different escape mechanisms, so antigen loss through TNFRSF17 deletion, which drives resistance to BCMA agents, does not affect it; T-cell fitness is the limitation the two share. The evidence comes from the cohort of MonumenTAL-1 that enrolled patients previously treated with T-cell redirection, and the RedirecTT-1 combination of teclistamab with talquetamab has shown high response rates including in extramedullary disease. The data are phase 1/2 and phase 3 combination trials are ongoing; the MajesTEC-1 paper on teclistamab links here.
Shares Talquetamab, Teclistamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares MonumenTAL-1, Talquetamab, Relapsed or refractory multiple myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares GPRC5D, Talquetamab, MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab.
Shares MonumenTAL-1, GPRC5D, Multiple myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares GPRC5D, Talquetamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/